Upcoming Events
  1. ***UPDATED*** ALTG Members’ Meeting, Sydney NSW

    November 24
  2. ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW

    November 24 @ 9:00 am - November 25 @ 5:00 pm UTC+10

ALTG Portfolio

Ongoing trials

  • ALTG 14/001 BR.31: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
  • ALTG 15/003 DREAM: A phase II trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in
  • ALTG 14/002 NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapy
  • ALTG 13/008 PEARL: Investigating the impact of early palliative care

Concepts in development – view details

  • ALTG 15/004 BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk advanced or metastatic (stage IIIB/IV) squamous or non-squamous NSCLC
  • ALTG 16/002 Fear of recurrence in patients with early stage NSCLC
  • ALTG 16/003 Optimal duration of treatment with immunotherapy (NSCLC)
  • ALTG 16/004 SCRIBE: A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastases
  • ALTG 16/005 OSCILLATE: Alternating Osimertinib and Gefitinib in patients with EGFR T790M positive NSCLC
  • ALTG 16/007 ALKTERNATE: Randomized Phase 2 study of fixed alternating crizotinib/lortatinib versus sequential crozotinib followed by lortalinib, as first line therapy in ALK gene rearranged NSCLC
  • ALTG 16/008 NINA: Phase 2 single arm study of nintedanib in combination with avelumab as second line therapy in patients with advanced lung adenocarcinoma
  • ALTG 16/009 A Phase 2 study of durvalumab plus tremelimumab in patients with relapsed EGFR mutant non-small cell lung cancer
  • ALTG 16/010 LungCare: A multicentre randomised controlled trial comparing primary care vs hospital-based follow-up following surgical lobectomy for NSCLC
  • ALTG 16/012 STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy
  • ALTG 17/001 Active surveillance in patients with Malignant Pleural Mesothelioma, a prospective single arm phase II trial

Endorsed trials – in development and ongoing

  • ALTG 16/013 Activities and influences of the specialist lung cancer nurse: a mixed-method comparative study of the multidisciplinary team assigned and not assigned a specialist lung cancer nurse
  • ALTG 16/011 CORE: Conventional care Or Radioablation for Extracranial metastases
  • ALTG 15/001 SABR-OS: A randomised phase II trial to test the feasibility of randomising patients with peripheral stage I non-small cell lung cancer to either Stereotactic Ablative Radiotherapy (SABR) Or Surgery
  • ALTG 13/004 OPAL: Online and Phone Assistance for Lung cancer
  • ALTG 13/003 Rekindle: testing an online resource to promote sexual wellbeing for both patients and their partners
  • ALTG 13/002 Health related quality of life in Malignant Mesothelioma
  • ALTG 13/001 TROG 13.01 SAFRON II: Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial
  • ALTG 10/001 PLUNG: Randomised phase III trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy
  • ALTG 09/005 TROG 09.02 CHISEL: Phase III randomised trial of highly conformal hypofractionated image guided (“stereotactic”) radiotherapy vs conventionally fractionated radiotherapy for inoperable early stage I NSCLC